Bosentan reduces pulmonary artery pressure in high altitude residents

High Altitude Medicine and Biology

Volumn 13, Issue 3, 2012, Pages 217-223

  Kojonazarov, Baktybek ^a,b   Isakova, Jainagul ^a   Imanov, Bakytbek ^c   Sovkhozova, Nurmira ^a   Sooronbaev, Talantbek ^c   Ishizaki, Takeshi ^d   Aldashev, Almaz A ^a  

^a Institute of Molecular Biology and Medicine   (Kyrgyzstan)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^c National Center of Cardiology and Internal Medicine   (Kyrgyzstan)

^d UNIVERSITY OF FUKUI   (Japan)

Author keywords

bosentan; endothelin 1; highlanders; pulmonary hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN 1; GENOMIC DNA;

ADULT; ALLELE; ALTITUDE; ALTITUDE ACCLIMATIZATION; CONFERENCE PAPER; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KYRGYZSTAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SINGLE DRUG DOSE;

ADULT; AGED; ALTITUDE; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; ENDOTHELIN-1; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PULMONARY ARTERY; SULFONAMIDES;

EID: 84866638497     PISSN: 15270297     EISSN: 15578682     Source Type: Journal    
DOI: 10.1089/ham.2011.1107     Document Type: Conference Paper

References (43)

1. Aldashev AA. (2000). High-altitude pulmonary hypertension and signal transduction in the cardiovascular system. J Receptor Signal Transduc Res 20:255-278.
2. Aldashev AA, Sarybaev AS, Sydykov AS, Kalmyrzaev BB, Kim EV, Mamanova LB, Maripov R, Kojonazarov BK, Mirrakhimov MM, Wilkins MR, and Morrell NW. (2002). Characterization of high-altitude pulmonary hypertension in the Kyrgyz: Association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med 166:1396-1402. (Pubitemid 35292708)
3. Aldashev AA, Kojonazarov BK, Amatov TA, Sooronbaev TM, Mirrakhimov MM, Morrell NW, Wharton J, and Wilkins MR. (2005). Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 60:683-687. (Pubitemid 41129068)
4. Arias-Stella J and Saldana M. (1963). The terminal portion of the pulmonary arterial tree in people native to high altitudes. Circulation 28:915-925.
5. Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noe E, Piette JC, Godeau P, and Gandjbakhch I. (1997). Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33:196-200. (Pubitemid 27019115)
6. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, and Rubin LJ. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 358:1119-1123. (Pubitemid 32971843)
7. Chow LC, Dittrich HC, Hoit BD, Moser KM, and Nicod PH. (1988). Doppler assessment of changes in right-sided cardiac hemodynamics after pulmonary thromboendarterectomy. Am J Cardiol 61:1092-1097.
8. Droma Y, Hayano T, Takabayashi Y, Koizumi T, Kubo K, Kobayashi T, and Sekiguchi M. (1996). Endothelin-1 and interleukin-8 in high altitude pulmonary oedema. Eur Respir J 9:1947-1949.
9. Droma Y, Hanaoka M, Ota M, Katsuyama Y, Koizumi T, Fujimoto K, Kobayashi T, and Kubo K. (2002). Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. Circulation 106:826-830.
10. Droma Y, Hanaoka M, Basnyat B, Arjyal A, Neupane P, Pandit A, Sharma D, Miwa N, Ito M, Katsuyama Y, Ota M, and Kubo K. (2006). Genetic contribution of the endothelial nitric oxide synthase gene to high altitude adaptation in sherpas. High Alt Med Biol 7:209-220.
11. Faoro V, Boldingh S, Moreels M, Martinez S, Lamotte M, Unger P, Brimioulle S, Huez S, and Naeije R. (2009). Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. Chest 135:1215-1222.
12. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, and Stewart DJ. (1993). Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J Med 328:1732-1739.
13. Goerre S, Wenk M, Bartsch P, Luscher TF, Niroomand F, Hohenhaus E, Oelz O, and Reinhart WH. (1995). Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation 91:359-364.
14. Grover RF, Vogel JH, Voigt GC, and Blount SG, Jr. (1966). Reversal of high altitude pulmonary hypertension. Am J Cardiol 18:928-932.
15. Groves BM, Reeves JT, Sutton JR, Wagner PD, Cymerman A, Malconian MK, Rock PB, Young PM, and Houston CS. (1987). Operation Everest II: Elevated high-altitude pulmonary resistance unresponsive to oxygen. J Appl Physiol 63:521-530.
16. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, and Rabinovitch M. (2004). Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S-24S.
17. Kitabatake A, Inoue M, Asao M, Masuyama T, Tanouchi J, Morita T, Mishima M, Uematsu M, Shimazu T, Hori M, and Abe H. (1983). Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 68: 302-309. (Pubitemid 13028906)
18. Kojonazarov BK, Imanov BZ, Amatov TA, Mirrakhimov MM, Naeije R, Wilkins MR, and Aldashev AA. (2007). Noninvasive and invasive evaluation of pulmonary arterial pressure in highlanders. Eur Respir J 29:352-356.
19. Kosturakis D, Goldberg SJ, Allen HD, and Loeber C. (1984). Doppler echocardiographic prediction of pulmonary arterial hypertension in congenital heart disease. Am J Cardiol 53:1110-1115.
20. Leon-Velarde F, Maggiorini M, Reeves JT, Aldashev A, Asmus I, Bernardi L, Ge RL, Hackett P, Kobayashi T, Moore LG, Penaloza D, Richalet JP, Roach R, Wu T, Vargas E, Zubieta-Castillo G, and Zubieta-Calleja G. (2005). Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 6:147-157.
21. Li H, Elton TS, Chen YF, and Oparil S. (1994). Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 266:L553-560.
22. MacLean MR. (1998). Endothelin-1: A mediator of pulmonary hypertension? Pulmon Pharmacol Therap 11:125-132.
23. Modesti PA, Vanni S, Morabito M, Modesti A, Marchetta M, Gamberi T, Sofi F, Savia G, Mancia G, Gensini GF, and Parati G. (2006). Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) Study. Circulation 114:1410-1416.
24. Morrell NW, Sarybaev AS, Alikhan A, Mirrakhimov MM, and Aldashev AA. (1999). ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders. Lancet 353:814. (Pubitemid 29110417)
25. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, and Rich S. (1995). Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26:1581-1585.
26. Olfert IM, Loeckinger A, Treml B, Faulhaber M, Flatz M, Burtscher M, Truebsbach S, and Kleinsasser A. (2011). Sildenafil and bosentan improve arterial oxygenation during acute hypoxic exercise: A controlled laboratory trial. Wilderness Environ Med 22:211-221.
27. Penaloza D and Sime F. (1971). Chronic cor pulmonale due to loss of altitude acclimatization (chronic mountain sickness). Am J Med 50:728-743.
28. Pham I, Wuerzner G, Richalet JP, Peyrard S, and Azizi M. (2010). Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. Eur J Clin Invest 40:195-202.
29. Rajput C, Najib S, Norboo T, Afrin F, and Qadar Pasha MA. (2006). Endothelin-1 gene variants and levels associate with adaptation to hypobaric hypoxia in high-altitude natives. Biochem Biophys Res Commun 341:1218-1224.
30. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, and Simonneau G. (2002). Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 346:896-903.
31. Sartori C, Vollenweider L, Loffler BM, Delabays A, Nicod P, Bartsch P, and Scherrer U. (1999). Exaggerated endothelin release in high-altitude pulmonary edema. Circulation 99:2665-2668.
32. Seheult RD, Ruh K, Foster GP, and Anholm JD. (2009). Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. Respir Physiol Neurobiol 165:123-130.
33. Shirakami G, Nakao K, Saito Y, Magaribuchi T, Jougasaki M, Mukoyama M, Arai H, Hosoda K, Suga S, Ogawa Y, et al. (1991). Acute pulmonary alveolar hypoxia increases lung and plasma endothelin-1 levels in conscious rats. Life Sci 48: 969-976.
34. Stewart DJ, Levy RD, Cernacek P, and Langleben D. (1991). Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Int Med 114:464-469.
35. Tanaka C, Kamide K, Takiuchi S, Kawano Y, and Miyata T. (2004). Evaluation of the Lys198Asn and - 134delA genetic polymorphisms of the endothelin-1 gene. Hyperten Res 27:367-371.
36. Vasku A, Spinarova L, Goldbergova M, Muzik J, Spinar J, Vitovec J, Toman J, and Vacha J. (2002). The double heterozygote of two endothelin-1 gene polymorphisms (G8002A and - 3A/-4A) is related to big endothelin levels in chronic heart failure. Exp Mol Pathol 73:230-233.
37. Wagner OF, Vierhapper H, Gasic S, Nowotny P, and Waldhausl W. (1992). Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 22:277-282.
38. Weir EK, Tucker A, Reeves JT, Will DH, and Grover RF. (1974). The genetic factor influencing pulmonary hypertension in cattle at high altitude. Cardiovasc Res 8:745-749.
39. Westcott RN, Fowler NO, Scott RC, Hauenstein VD, and Mc GJ. (1951). Anoxia and human pulmonary vascular resistance. J Clin Invest 30:957-970.
40. Whitman EM, Pisarcik S, Luke T, Fallon M, Wang J, Sylvester JT, Semenza GL, and Shimoda LA. (2008). Endothelin-1 mediates hypoxia-induced inhibition of voltage-gated K+ channel expression in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 294:L309-318.
41. Yanagisawa M and Masaki T. (1989). Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharmacol 38:1877-1883. (Pubitemid 19149179)
42. Yang X, Chen W, and Chen J. (1997). Change of level and expression of endothelin-1 in the lungs of rats with hypoxic pulmonary hypertension. Chinese Med J 110:104-108.
43. Yock PG and Popp RL. (1984). Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70:657-662.